arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Serina Therapeutics, Inc.

SER

$2.39 ▲ +0.03 (+1.27%) at close

9 Visible periods

31 Metrics

Absolute Benchmarks

Price Chart

Health

Poor

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Serina Therapeutics, Inc. shows mixed fundamentals. Return on Invested Capital remain bright spots. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $24.4M

Dividend Yield —

Revenue Growth 132.1% ↗

Op. Margin None

ROIC 64985.2% ↗

FCF / Share $-1.77 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$130.00K

↑ +132.1% —

Net Income Profit after all expenses

$-19.18M

↓ -72.2% —

Operating Margin Operating profit as % of sales

-99.2%

↑ +79.1% —

FCF / Share Free cash flow per share

$-1.77

↑ +24.2% —

Long-Term Debt Long-term obligations

$18.12M

↑ +37.3% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

Return on Invested CapitalReturn on Invested Capital of 64985.2% is excellent on an absolute basis (target > 10%)

warning

Bearish Risks

Interest CoverageInterest Coverage of -1413.06x is weak on an absolute basis (target > 5x)
FCF / Net IncomeFCF / Net Income of 0.94x is caution on an absolute basis (target > 1x)

Health Breakdown

Financial Health ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	132.1% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1552%)	-98.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1328%)	9173.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+114569%)	-76.4% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1055%)	-60.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-851%)	-74.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1027%)	-0.6% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-107%)	—	—
EPS Growth YoY (%)	-26.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-21.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-72.2% Weak Weak Year-over-year change in net income	N/M	N/M	-20.6% Weak ↓ Weak Declining Year-over-year change in net income	20.2% Good ↑ Good Improving Year-over-year change in net income	-44.8% Weak Weak Year-over-year change in net income	-14.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	24.2% Good ↑ Good Improving Year-over-year change in free cash flow	-110.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	99.4% Excellent Excellent Year-over-year change in free cash flow	24.5% Good Good Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	56.4% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-27.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	105.9% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-71.0% Weak Weak Compound annual revenue growth over 3 years	-53.2% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-18.5% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	-47.4% Weak Weak Compound annual revenue growth over 5 years	17.6% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	—	—	-99.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-762%)	—	—	—	—	-474.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3264%)	—
Effective Tax Rate (%) (%)	-0.1% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	1.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	—	—	—	—	—	—	—	-468.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4006%)	—
FCF Margin (%) (%)	—	—	-78.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	-447.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.54x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.47x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.57x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	64985.2% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-2659.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	9.7% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	-604.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-457.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	194.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-119.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-72.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-345.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-253.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-215.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-251.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-257.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-105.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-69.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	-16.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	60.8% Excellent → Excellent Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+305%)	73.3% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+389%)	212.4% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1316%)	-100.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-772%)	-90.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-703%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Debt to Equity (x)	—	—	—	-1.05x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-275%)	-1.12x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-286%)	—	—	—	—
Interest Coverage (x)	-1413.06x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-2.09x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-7.23x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-841.67x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-1022.27x Weak Weak Operating income divided by interest expense Optimal: > 5x	-740.33x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-3.06M	$-3.67M	$-7.62M	$17.48M	$12.62M	$-527.00K	$-6.71M	$-7.38M	$-259.00K
Debt / EBITDA (x)	—	—	—	-2.60x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.66x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$0.01	$0.01	$1.41	$1.11	$4.71	—	—	—	—
Basic EPS, GAAP (USD)	$-1.91	$-1.51	$2.36	$-346.75	$-284.83	—	—	—	—
Free Cash Flow per Share (USD)	$-1.77	$-2.33	$-1.11	$-193.83	$-256.76	—	—	—	—
Book Value per Share (USD)	$-0.00	$0.07	$-13.40	$-561.68	$-386.19	$-168.09	$257.39	$267.13	—
Tangible Book Value per Share (USD)	$-0.00	$0.07	$-13.40	$-585.76	$-414.59	$-220.40	$163.76	$198.36	—
Basic Weighted Avg Shares (shares)	10.19M	7.36M	2.23M	30,640	30,593	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Working Capital (USD)	$2.52M	$3.31M	$6.21M	$-7.62M	$-6.73M	$-3.07M	—	—	—
LT Debt (USD)	—	—	—	$18.12M	$13.20M	—	—	—	—
Total Equity (USD)	$-37.00K	$641.00K	$-32.29M	$-17.21M	$-11.83M	$-5.12M	$7.45M	$7.28M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2018 10-K ↗	FY 2018 Dec 31, 2017 10-K ↗	FY 2017 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$130.00K	$56.00K	$3.15M	$34.00K	$144.00K	$361.00K	$1.40M	$1.40M	—
Depreciation Expense (USD)	$100.00K	$100.00K	—	—	—	$699.00K	$58.00K	$165.00K	—
Net Income, GAAP (USD)	$-19.18M	$-11.14M	$5.27M	$-10.46M	$-8.68M	$-10.87M	$-7.50M	$-6.58M	—
Operating Cash Flow (USD)	$-17.95M	$-17.14M	$-2.48M	$-5.94M	$-7.86M	$-7.82M	$-8.00M	$-6.29M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 32 quarters

Serina Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare SER with peers